CN114698698A - Medical fat component formula food and preparation method thereof - Google Patents
Medical fat component formula food and preparation method thereof Download PDFInfo
- Publication number
- CN114698698A CN114698698A CN202210301024.5A CN202210301024A CN114698698A CN 114698698 A CN114698698 A CN 114698698A CN 202210301024 A CN202210301024 A CN 202210301024A CN 114698698 A CN114698698 A CN 114698698A
- Authority
- CN
- China
- Prior art keywords
- oil
- component formula
- fat
- fat component
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 239000003921 oil Substances 0.000 claims abstract description 28
- 235000019198 oils Nutrition 0.000 claims abstract description 28
- 239000010495 camellia oil Substances 0.000 claims abstract description 22
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000019484 Rapeseed oil Nutrition 0.000 claims abstract description 11
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 10
- 239000003813 safflower oil Substances 0.000 claims abstract description 10
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 10
- 244000248162 Xanthoceras sorbifolium Species 0.000 claims abstract description 6
- 235000009240 Xanthoceras sorbifolium Nutrition 0.000 claims abstract description 6
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 2
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 23
- 238000002156 mixing Methods 0.000 claims description 20
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 9
- 238000011049 filling Methods 0.000 claims description 7
- 238000007789 sealing Methods 0.000 claims description 7
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 17
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract description 11
- 230000003405 preventing effect Effects 0.000 abstract description 11
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 230000029087 digestion Effects 0.000 abstract description 4
- 235000015097 nutrients Nutrition 0.000 abstract description 4
- 239000003925 fat Substances 0.000 description 45
- 235000019197 fats Nutrition 0.000 description 45
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 239000003549 soybean oil Substances 0.000 description 16
- 235000012424 soybean oil Nutrition 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 12
- 235000020778 linoleic acid Nutrition 0.000 description 12
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 10
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 9
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 9
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 9
- 239000005642 Oleic acid Substances 0.000 description 9
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 9
- 235000021313 oleic acid Nutrition 0.000 description 9
- 241000736199 Paeonia Species 0.000 description 8
- LRFDUPNLCDXZOE-UHFFFAOYSA-N camellianin b Chemical compound OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(OC=2C=3C(=O)C=C(OC=3C=C(O)C=2)C=2C=CC(O)=CC=2)OC1CO LRFDUPNLCDXZOE-UHFFFAOYSA-N 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 239000004006 olive oil Substances 0.000 description 8
- 235000008390 olive oil Nutrition 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 7
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 6
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 6
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 6
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 6
- 229960004488 linolenic acid Drugs 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 241001122767 Theaceae Species 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 239000008157 edible vegetable oil Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000000050 nutritive effect Effects 0.000 description 5
- 150000004671 saturated fatty acids Chemical class 0.000 description 5
- 240000002791 Brassica napus Species 0.000 description 4
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 240000007124 Brassica oleracea Species 0.000 description 3
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 3
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 3
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000019485 Safflower oil Nutrition 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 239000010699 lard oil Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- -1 oryzanol Natural products 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 235000005713 safflower oil Nutrition 0.000 description 3
- 235000003441 saturated fatty acids Nutrition 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- 235000019737 Animal fat Nutrition 0.000 description 2
- 108010004103 Chylomicrons Proteins 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- 241000612118 Samolus valerandi Species 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 150000002711 medium chain fatty acid esters Chemical class 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- HUJXHFRXWWGYQH-UHFFFAOYSA-O sinapine Chemical compound COC1=CC(\C=C\C(=O)OCC[N+](C)(C)C)=CC(OC)=C1O HUJXHFRXWWGYQH-UHFFFAOYSA-O 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 239000003760 tallow Substances 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 206010002482 Angiosclerosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000147058 Derris elliptica Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004392 development of vision Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 210000004258 portal system Anatomy 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/02—Other edible oils or fats, e.g. shortenings, cooking oils characterised by the production or working-up
- A23D9/04—Working-up
Landscapes
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Edible Oils And Fats (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention belongs to the field of food, and particularly relates to medical fat component formula food and a preparation method thereof. The fat component formula food for special medical application comprises the following components in parts by weight: 40-60 parts of medium-chain triglyceride, 12-17 parts of peony seed oil, 10-15 parts of rapeseed oil, 8-12 parts of camellia oil, 5-10 parts of safflower seed oil and 3-8 parts of shinyleaf yellowhorn oil. The fat component formula food for special medical application provided by the invention takes medium-chain fat and long-chain fat as fat sources, and the proportion of the medium-chain fat to the long-chain fat is 1: 1, balanced nutrient components, quick digestion and absorption, and capability of quickly providing energy, and has good effects of relieving and preventing hypertriglyceridemia.
Description
Technical Field
The invention belongs to the field of food, and particularly relates to medical fat component formula food and a preparation method thereof.
Background
Hypertriglyceridemia (HTG) is a disorder of the synthesis or degradation of an alien triglyceride protein, resulting in an increased level of triglycerides in the blood. The hypertriglyceridemia can cause lipid to deposit on the blood vessel wall, small plaques are gradually formed, the plaques are gradually enlarged, the inner diameter of the blood vessel is reduced, the blood flow is slow, the process of blocking the blood vessel is accelerated, and the hypertriglyceridemia can be caused to cause coronary heart disease, myocardial infarction, cerebral infarction and eyeground vascular lesion to cause visual deterioration and even blindness, so the method has extremely important significance on preventing and relieving the hypertriglyceridemia.
Medium chain triglycerides are naturally present in food products such as palm kernel oil, coconut oil, and breast milk, and are one of the sources of dietary fat, with the major components being caprylic and capric glycerides.
The hydrolysis of triglyceride in human body is only in 1,3 position fatty acid, 2 position is absorbed in the form of 2-monoglyceride, when 1,3 position are medium chain fatty acid and 2 position is long chain fatty acid, the hydrolysis and absorption speed of triglyceride is fastest, medium and long chain fatty acid triglyceride can provide fatty acid necessary for human body and can be quickly oxidized to supply energy compared with common vegetable oil, and can maximally exert the nutritive value and physiological function of various fatty acids.
Medium chain triglycerides are composed of only saturated fatty acids, have low freezing points, are liquid at room temperature, and have low viscosities. Compared with soybean oil, the liquid is completely odorless and colorless transparent liquid. Compared with common oil and fat and hydrogenated oil and fat, the medium chain triglyceride has very low unsaturated fatty acid content, very high oxidation stability and iodine value not higher than 0.5. Medium chain triglycerides are particularly stable at high and low temperatures.
The peony seed oil is rich in nutrition, has special effects of resisting aging, prolonging life, activating peripheral nerves and the like, has prevention and improvement effects on cardiovascular and cerebrovascular diseases, reducing blood fat, lowering blood pressure, preventing and resisting cancer, resisting radiation, protecting vision, enhancing intelligence and the like, can eliminate pigment accumulated spots, reduce wrinkles, enable skin to be fine, smooth and clean, and is rich in elasticity, and particularly has great influence on the development of vision, brain and organisms of the baby fetus.
The peony seed oil is edible oil with the most balanced contents of oleic acid, linoleic acid and alpha-linolenic acid. Through the determination of nutrient components of the peony seed oil by professional institutions, in the peony seed oil produced by white-phoenix and purple-spotted peonies which are oil-used peony crops, the content ratio of oleic acid, linoleic acid and alpha-linolenic acid is 1: 1: 1.5.
rapeseed oil is oil with high erucic acid content, and the absorption rate of human body to rapeseed oil is high and can reach 99%. The rapeseed oil has certain efficacies of softening blood vessels and delaying senility.
The rapeseed oil is mainly obtained from seeds of cabbage type rape and cabbage type rape. Contains protein 21-27 wt% and phospholipid 1 wt%. The rapeseed oil is obtained by pressing Chinese cabbage type rapeseed, and most of the planted rape is cabbage type rape. Through planting and cultivation, the erucic acid content of many varieties is lower than 3%. The fatty acid compositions of rapeseed vary widely from place to place, and some rapeseed contain more than 50% oleic acid.
The rapeseed oil contains 0.4-1.0% of arachidic acid, 14-19% of oleic acid, 12-24% of linoleic acid, 31-55% of erucic acid and 1-10% of linolenic acid. From the aspect of nutritive value, the human body has a digestion and absorption rate of 99 percent to the rapeseed oil, and is beneficial to the gallbladder function. Under the pathological condition of liver, the rapeseed ketone can be normally metabolized by human body. In addition, rapeseed oil contains a small amount of erucic acid and sinapine, and the substances are generally considered to be unfavorable for the growth and development of human bodies. If the linoleic acid can be matched with excellent edible oil rich in linoleic acid for eating, the nutritive value of the linoleic acid can be improved.
The camellia oil does not contain erucic acid and cholesterol. After testing: the camellia oil contains more than 90% of unsaturated fatty acid, 80-83% of oleic acid and 7-13% of linoleic acid.
The camellia oil does not contain harmful substances to human bodies, such as erucic acid, cholesterol, aflatoxin and the like. The comparative study of tea oil and olive oil shows that the tea oil has better dietetic therapy double functions than olive oil and any other oil despite the similarity of the components of the tea oil and the olive oil. The olive oil contains 75-90% of unsaturated fatty acid, and the tea oil contains 85-97% of unsaturated fatty acid, which is the crown of various edible oils. The tea oil contains tea polyphenol and camellin which are specific physiological active substances not contained in olive oil, can effectively improve cardiovascular and cerebrovascular diseases, reduce cholesterol and fasting blood sugar, inhibit the increase of triglyceride, and has obvious effect on inhibiting cancer cells. The camellia oil is divided into crude camellia oil, 2-level camellia oil and 1-level camellia oil according to different grades of color, smell and acidity. The camellia oil is rich in nutrition, contains fatty acid, camellin, tea polyphenol, saponin, tannin, squalene with antioxidant and anti-inflammatory effects, squalene and flavonoid substances, and has an excellent effect on resisting cancers. The camellia oil is also rich in vitamin E, calcium, iron, zinc and other trace elements, and the zinc content of the camellia oil is 10 times of that of the soybean oil.
The unsaturated fatty acids in camellia oil exceed those in olive oil. The unsaturated fatty acid in the camellia oil is up to 85-97 percent and is the crown of various edible oils. The camellia oil contains tea polyphenol and camellin which are specific physiological active substances not contained in olive oil. The tea polyphenol and camellin in the camellia oil have obvious effects of reducing cholesterol and resisting cancer, and are antioxidant and storage-resistant.
The peony seed oil contains more than 43 percent of alpha-linolenic acid, has very obvious promotion effect on the intelligence development of children, and has especially obvious effect on improving the intelligence deterioration of the old. Alpha-linolenic acid is an unsaturated fatty acid that can be metabolized in the human body to DHA and EPA. DHA and EPA can be directly absorbed by human body, nourish brain cells, and promote division and growth of brain cells; promoting the development of cranial nerve and optic nerve, improving brain memory, enhancing logical thinking ability, and improving eyesight.
Safflower seed oil is also called safflower oil, and is an oil product prepared from safflower seeds. The fatty acid components of the safflower seed oil comprise 5-9% of palmitic acid, 1-4.9% of stearic acid, 11-15% of oleic acid and 69-79% of linoleic acid. Oleic safflower oil is mainly composed of oleic acid (about 60%) and linoleic acid (25%). The oil contains vitamin E, oryzanol, sterol, and other nutrients, and has effects of preventing and treating arteriosclerosis and reducing blood cholesterol.
Safflower oil contains 6% saturated fatty acid, 21% oleic acid and 73% linoleic acid. Because the main component of the health care food is linoleic acid which is the highest linoleic acid in the food oil, the health care food has high nutritive value and can play a role in preventing the deposition of serum cholesterol in the blood vessel wall of a human body and preventing and treating atherosclerosis and cardiovascular diseases. In medicine, safflower seed oil can be used for preparing medicines for preventing and treating cardiovascular diseases, hypertension and liver cirrhosis. In addition, the safflower seed oil also contains a large amount of medicinal components such as vitamin E, oryzanol, sterol, etc.
The shinyleaf yellowhorn has high nutritive value, and the oil content in seeds and kernels is extremely high. The research result proves that: the oil content in the kernel reaches 66.39%, the oil content in the kernel of the fine variety reaches 72%, and the oil content is higher than that of the common oil plants, and the basic composition of the oil is as follows: stearic acid, oleic acid 38.9% and linoleic acid 40.2%, close to soybean oil, walnut oil, and it is the most nutritious parts, behenic acid 7.2% linolenic acid and glycerenoic acid are 0.3% each, xanthoceras sorbifolia bunge seeds are economic woody oil tree species, the oil content of seeds is 30.4% -47%, the oil content of seeds is 66.39%, the edible xanthoceras sorbifolia bunge oil can effectively prevent diseases such as hypertension, hyperlipemia, angiosclerosis, etc.
The length of the fatty acid carbon chain is determined by the carbon content, and a fatty chain having 4 to 6 carbon atoms is referred to as a short-chain fatty acid, a fatty chain having 8 to 12 carbon atoms is referred to as a medium-chain fatty acid, and a fatty chain having 14 or more carbon atoms is referred to as a long-chain fatty acid. The most widely contacted in daily life are long-chain fatty acids, such as lard, beef tallow, mutton fat, chicken oil, fish oil and the like in animal fat, peanut oil, soybean oil, corn oil, sunflower oil, sesame oil, olive oil and the like in vegetable oil, wherein the main components of the fats are long-chain fatty acids, and the medium-chain fatty acids exist in small amount in the animal fat, such as fat of pigs, cattle and sheep, the medium-chain fatty acids are higher in beef tallow and account for about 3-4% of the total fat, and the content of the lard is only about 1%. Medium chain fatty acids are also present in some foods, such as silky fowl, coconut, milk, palm, breast milk, beef, mutton, fish, etc., with coconut, palm, breast milk, silky fowl, and milk being abundant.
The long-chain fatty acids include various fatty acids such as saturated fatty acids, monounsaturated fatty acids, and polyunsaturated fatty acids, and the medium-chain fatty acids are not saturated fatty acids in the family. The medium-chain saturated fatty acid not only can not increase the cholesterol level in blood, but also has the function of reducing cholesterol and has a definite regulation effect on various chronic diseases.
Medium-chain fatty acids enter the liver through the portal system, unlike long-chain fatty acids, which are recombined with glycerol to form triglycerides in the epithelial cells of the intestinal tract and then participate in the formation of chylomicrons before entering the blood circulation via the lymphatic system. Therefore, medium-chain fatty acids are absorbed rapidly in the human body. Generally, the fat can be digested in a human body within 3-4 hours, while the medium-chain fatty acid can be directly absorbed from epithelial cells of the intestinal tract within a few minutes and then enters the blood circulation through the hepatic portal vein for utilization. Thus, the medium-chain fatty acid is not easy to deposit in vivo, and has certain effect on losing weight.
The medium-chain fatty acid does not need to form chylomicron with other lipid substances during transportation, and is not easy to combine with protein to form lipoprotein. Therefore, the cholesterol content in blood can not be increased, and the blood fat reducing tea has a certain regulating effect.
Because the medium-chain fat directly enters the liver through veins without passing through a lymphatic system and does not contain lipid in the liver, the medium-chain fat is not easy to form fatty liver and has protective effect on the liver. Because of the characteristics of medium-chain fatty acids, medium-chain fats are often used as edible oils for patients with pancreatic and hepatobiliary diseases, and when the medium-chain fats are ingested by the human body, the secretion of pancreatic juice can be caused.
Therefore, it is an important subject to develop a special medical-purpose fat component formula food for preventing and relieving hypertriglyceridemia, which fills up the blank of special medical-purpose fat component formula food special for hypertriglyceridemia patients in the current market.
Disclosure of Invention
The invention aims to solve the technical problem of providing a fat component formula food with special medical application and a preparation method thereof, wherein medium-chain fat and long-chain fat are used as fat sources, the fat component formula food has balanced nutrient components, is fast in digestion and absorption, can quickly provide energy, and has good relieving and preventing effects on hypertriglyceridemia.
The invention provides a medical fat component formula food which comprises the following components in parts by weight:
preferably, the medical fat component formula food comprises the following components in parts by weight:
the medium chain triglyceride can be used as special food for patients after operation, infection and skin burn, can also be used for food for patients with fat malabsorption due to reasonable adjustment of long chain fatty acid and medium chain fatty acid, AIDS patients, cancer patients and diabetes, and can be used for treating prostatic hyperplasia, reducing cholesterol and preventing and treating hyperlipidemia. In addition, the medium chain fatty acid ester can help to lose weight, and has remarkable effects on reducing the body weight and the abdominal fat area of a human body by eating the medium chain fatty acid ester.
Preferably, the mass ratio of the caprylin to the caprin in the medium chain triglyceride is 55-57: 43-45.
Preferably, the mass ratio of the medium-chain fatty acid (C6-C12) content to the long-chain fatty acid (C14-C24) in the medical fat component formula food is 44-52: 48-54.
The long chain fatty acid can not only meet the energy requirement of the organism, but also ensure the requirement of the essential fatty acid.
Because the medium-chain fatty acid has small molecular weight, high solubility and low melting point, the hydrolysis is quicker and more sufficient. Therefore, the medium-chain fatty acid has excellent solubility in the living body, and is hydrolyzed more sufficiently particularly by the pancreatic lipase, and is absorbed more easily by the body. Even in the case of pancreatic lipase and bile salt deficiency, medium-chain fatty acids can be absorbed in the form of triacylglycerols due to their small molecular size, high solubility, rapid hydrolysis, and the like.
Based on the advantages, the proportion of the long-chain fatty acid and the medium-chain fatty acid is reasonably adjusted, and the medical fat component formula food meeting the fat requirements of target people can be obtained.
The invention also provides a preparation method of the medical fat component formula food, which adopts a mixing and stirring method to prepare the medical fat component formula food.
Preferably, the preparation method comprises the following steps:
(1) mixing the medium-chain triglyceride, the peony seed oil, the rapeseed oil, the camellia oil, the safflower seed oil and the shinyleaf yellowhorn oil to obtain a mixed component;
(2) and filling and sealing the mixed components to obtain the medical fat component formula food.
Further, in the step (1), the mixing time is 30-40 min.
Further, in the step (1), the mixing stirring speed is 50-60 r/min.
Further, in the step (1), the mixing temperature is 20-30 ℃.
Compared with the prior art, the technical scheme of the invention has the following advantages:
the medical fat component formula food provided by the invention takes medium-chain fat and long-chain fat as fat sources, and the proportion of the medium-chain fat to the long-chain fat is close to 1: 1, the nutritional ingredients are balanced, the digestion and absorption are fast, the energy is rapidly provided, the nutritional health food is suitable for people with hypertriglyceridemia, has good relieving and preventing effects on the hypertriglyceridemia, and can meet the fat demand of target people.
Detailed Description
The present invention is further described below in conjunction with specific examples to enable those skilled in the art to better understand the present invention and to practice it, but the examples are not intended to limit the present invention.
Example 1
The embodiment provides a fat component formula food for special medical application, which comprises the following components in parts by weight:
the embodiment also provides a preparation method of the food, which comprises the following steps:
(1) weighing the raw materials for later use;
(2) sequentially putting the raw materials into a mixing tank at 25 ℃ and mixing and stirring at a speed of 50r/min for 35min to obtain mixed oil;
(3) and (3) filling and sealing the mixed oil obtained in the step (2) to obtain the product.
Example 2
The embodiment provides a fat component formula food for special medical application, which comprises the following components in parts by weight:
the embodiment also provides a preparation method of the food, which comprises the following steps:
(1) weighing the raw materials for later use;
(2) sequentially putting the raw materials into a mixing tank at 25 ℃ and mixing and stirring at a speed of 50r/min for 35min for later use;
(3) and (4) filling and sealing the mixed oil obtained in the step (3) to obtain the product.
Example 3
The embodiment provides a fat component formula food for special medical application, which comprises the following components in parts by weight:
the embodiment also provides a preparation method of the food, which comprises the following steps:
(1) weighing the raw materials for later use;
(2) sequentially putting the raw materials into a mixing tank at 25 ℃ and mixing and stirring at a speed of 50r/min for 35min for later use;
(3) and (4) filling and sealing the mixed oil obtained in the step (3) to obtain the product.
Example 4
The embodiment provides a fat component formula food for special medical application, which comprises the following components in parts by weight:
the embodiment also provides a preparation method of the food, which comprises the following steps:
(1) weighing the raw materials for later use;
(2) sequentially putting the raw materials into a mixing tank at 20 ℃ and mixing and stirring at a speed of 60r/min for 40min for later use;
(3) and (4) filling and sealing the mixed oil obtained in the step (3) to obtain the product.
Example 5
The embodiment provides a fat component formula food for special medical application, which comprises the following components in parts by weight:
the embodiment also provides a preparation method of the food, which comprises the following steps:
(1) weighing the raw materials for later use;
(2) at 30 ℃, sequentially putting the raw materials into a mixing tank, and mixing and stirring at 50r/min for 30min for later use;
(3) and (4) filling and sealing the mixed oil obtained in the step (3) to obtain the product.
Effect evaluation 1
The improvement of postprandial blood lipids (triglyceride TG, total cholesterol TC) in mice was evaluated by comparative analysis for the fat component formula foods for special medical use prepared in example 1, example 2 and example 3.
50 mice are taken and randomly divided into 5 groups, namely a blank group, soybean oil (long-chain fatty acid), an example 1 group, an example 2 group and an example 3 group, after the mice are adaptively fed by basic feed for 1 week, the mice in each group are fasted for 18h (without water prohibition) and are gavaged, the gavage amount is that a sample of 0.1mg is gavaged per gram of the weight of the mice, an oil sample is diluted by 0.5 percent of CMC-Na solution, the mice in 3 groups are sequentially gavaged with physiological saline, soybean oil, the example 1 group, the example 2 group and the example 3 group, eyeball blood is taken after 4h, blood is centrifuged at 4000r/min for 5min, and the serum TG and TC contents are measured.
The improvement of blood lipid after meal in mice is shown in Table 1.
TABLE 1 postprandial blood lipid-related indices of mice
As can be seen from table 1, TG was significantly lower in the example 1 group, the example 2 group, and the example 3 group than in the soybean oil group, and significantly higher than the blank group. The TC was significantly lower in the example 1, example 2, and example 3 groups than in the soybean oil group, slightly higher than the blank group but with no significant difference. The results of the experiment thus show that the product of the invention (medium/long chain fatty acids) is able to inhibit the increase of TG and TC in the serum of mice in a short time compared to soybean oil (long chain fatty acids).
Effect evaluation 2
The fat component formula foods for special medical application prepared in example 1, example 2 and example 3 were evaluated for improvement of body weight, TG and TC in mouse growth experiments by comparative analysis.
60 mice were selected and randomly divided into 6 groups, each of which was a blank group, a lard group, a soybean oil group (long-chain fatty acid), a group of example 1, a group of example 2 and a group of example 3, and after 1 week of adaptive feeding from a basal diet, the mice were fed with the corresponding diet (see table 2), after 4 weeks of feeding (weighing one body weight per week), all the mice were fasted for 18 hours, and the eyes were removed to obtain blood, and the blood was centrifuged at 4000r/min for 5min, and then the serum contents of TG and TC were measured. The gavage amount is that each gram of mouse body weight gavage 0.1mg of sample, the oil sample is diluted by 0.5% CMC-Na solution, 3 groups of mice are sequentially gavaged with physiological saline, soybean oil, the group of example 1, the group of example 2 and the group of example 3, the eyeball blood is taken after 4 hours, the blood is centrifuged at 4000r/min for 5min, and the content of serum TG and TC is measured.
TABLE 2 feed formula for each group of mice
The effect of the product of the invention on the body weight of mice in the mouse growth experiments is shown in table 3.
TABLE 3 Effect of the invention on mouse body weight in mouse growth experiments
| Time | Blank group (g) | Lard oil (g) | Soybean oil (g) | EXAMPLE 1 group (g) | EXAMPLE 2 group (g) | EXAMPLE 3 group (g) |
| 1 week | 20.49±1.09 | 20.99±0.86 | 20.37±1.34 | 20.32±0.81 | 20.27±0.988 | 20.68±1.10 |
| 2 weeks | 25.32±2.13 | 30.21±0.94 | 28.55±1.17 | 27.92±1.15 | 28.91±1.41 | 28.64±1.65 |
| 3 weeks | 28.83±1.19 | 33.67±0.84 | 32.36±1.21 | 30.40±0.93 | 31.45±0.83 | 30.70±1.43 |
| 4 weeks | 30.22±1.18 | 36.28±0.97 | 35.25±0.98 | 32.65±1.10 | 33.49±1.19 | 32.45±0.50 |
As can be seen from table 3, there was no significant difference in body weight between the different groups at week 1, week 2 and week 3 after the start of the experiment; the weight average of the group of example 1, the group of example 2 and the group of example 3 was higher than that of the blank group and lower than that of the soybean oil group and the lard oil group at week 4. Thus, it is shown that the 3 examples of the present invention (medium/long chain fatty acids) showed significantly slower weight gain compared to the soybean oil (long chain fatty acids) and lard groups.
The effect of the present invention on TG and TC in mouse serum in mouse growth experiments is shown in Table 4.
TABLE 4 serum TG and TC content in mouse growth experiment
As can be seen from Table 4, TG and TC were lower in the example 1 group, the example 2 group and the example 3 group than in the lard oil group and the soybean oil group and higher than in the blank group. Thus, the experimental results show that the product of the invention (medium/long chain fatty acid) can inhibit the increase of TG and TC in mouse serum in a short time compared with soybean oil (long chain fatty acid) and lard.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications of the invention may be made without departing from the spirit or scope of the invention.
Claims (10)
1. The medical fat component formula food is characterized by comprising the following components in parts by weight:
2. the medical fat component formula food according to claim 1, consisting of the following components in parts by weight:
3. the medical fat component formula according to claim 1 or 2, wherein the mass ratio of caprylin and caprin in the medium chain triglycerides is 55-57: 43-45.
4. The medical fat component formula according to claim 1 or 2, wherein the mass ratio of long-chain fatty acids to medium-chain fatty acids in the medical fat component formula is 44-52: 48-54.
5. A method for preparing a medical fat component formula according to any one of claims 1 to 4, wherein the medical fat component formula is prepared by a mixing and stirring method.
6. The method of claim 5, comprising the steps of:
(1) mixing the medium-chain triglyceride, the peony seed oil, the rapeseed oil, the camellia oil, the safflower seed oil and the shinyleaf yellowhorn oil to obtain a mixed component;
(2) and packaging the mixed components to obtain the medical fat component formula food.
7. The method according to claim 6, wherein the mixing time in the step (1) is 30 to 40 min.
8. The method according to claim 6, wherein in the step (1), the stirring speed of the mixing is 50 to 60 r/min.
9. The method according to claim 6, wherein the mixing temperature in the step (1) is 20 to 30 ℃.
10. The method of claim 6, wherein in the step (2), the packaging method is sealing after filling.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210301024.5A CN114698698A (en) | 2022-03-25 | 2022-03-25 | Medical fat component formula food and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210301024.5A CN114698698A (en) | 2022-03-25 | 2022-03-25 | Medical fat component formula food and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114698698A true CN114698698A (en) | 2022-07-05 |
Family
ID=82170740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210301024.5A Withdrawn CN114698698A (en) | 2022-03-25 | 2022-03-25 | Medical fat component formula food and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114698698A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103380827A (en) * | 2012-05-02 | 2013-11-06 | 丰益(上海)生物技术研发中心有限公司 | Grease composition for preventing obesity fatty liver and preparation method thereof |
| CN104642563A (en) * | 2013-11-19 | 2015-05-27 | 丰益(上海)生物技术研发中心有限公司 | Flavor-stable grease composition |
| CN109965031A (en) * | 2019-03-29 | 2019-07-05 | 江南大学 | A kind of special medicine purposes formula food fat component formula and preparation method for inflammatory bowel disease |
| CN112772731A (en) * | 2021-01-22 | 2021-05-11 | 南昌大学 | Functional edible oil and preparation method and application thereof |
| CN114651967A (en) * | 2022-03-23 | 2022-06-24 | 浙江科露宝食品有限公司 | Infant nutritional supplement with special medical application and preparation method thereof |
-
2022
- 2022-03-25 CN CN202210301024.5A patent/CN114698698A/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103380827A (en) * | 2012-05-02 | 2013-11-06 | 丰益(上海)生物技术研发中心有限公司 | Grease composition for preventing obesity fatty liver and preparation method thereof |
| CN104642563A (en) * | 2013-11-19 | 2015-05-27 | 丰益(上海)生物技术研发中心有限公司 | Flavor-stable grease composition |
| CN109965031A (en) * | 2019-03-29 | 2019-07-05 | 江南大学 | A kind of special medicine purposes formula food fat component formula and preparation method for inflammatory bowel disease |
| CN112772731A (en) * | 2021-01-22 | 2021-05-11 | 南昌大学 | Functional edible oil and preparation method and application thereof |
| CN114651967A (en) * | 2022-03-23 | 2022-06-24 | 浙江科露宝食品有限公司 | Infant nutritional supplement with special medical application and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fraeye et al. | Dietary enrichment of eggs with omega-3 fatty acids: A review | |
| AU766660B2 (en) | Utilization of material containing docosapentaenoic acid | |
| CA2293338C (en) | Isomer enriched conjugated linoleic acid compositions | |
| KR100277808B1 (en) | Lcd device and method for producig the same | |
| US20100280112A1 (en) | Composition Enriched in Diglyceride with Conjugated Linoleic Acid | |
| CN101720822A (en) | Nutritional blend oil with balanced fatty acid component and active component for middle and old aged | |
| CN103444911A (en) | Medicinal and edible health care blending oil | |
| CN108720021A (en) | DHA algal oil microscapsule powder and preparation method thereof | |
| CN105053256A (en) | Flavored nutrition balanced blend oil | |
| Nguyen et al. | Supplementation with plant-derived oils rich in omega-3 polyunsaturated fatty acids for lamb production | |
| CN101810226A (en) | Fatty acid component balanced children type nutrition blended oil containing multiple active ingredients | |
| CN107683909A (en) | The special ready-mixed oil of high fat diet | |
| Ergönül et al. | Cold pressed camelina (Camelina sativa L.) seed oil | |
| CN108354175A (en) | Composition for relieving asthenopia containing flake, theanine and γ-aminobutyric acid | |
| CN107455331B (en) | Production method of DHA-rich nutritional health-care eggs | |
| KR100724165B1 (en) | Natural vegetable oil concentrated in unsaponifiable matters as food ingredient | |
| CN108185427A (en) | Composition for relieving asthenopia containing flake, theanine and phosphatidylserine | |
| CN108782786B (en) | Healthy edible black garlic blend oil and preparation method thereof | |
| CN109845840B (en) | Preparation method of saturated fatty acid and medium-long chain fatty acid structured lipid | |
| Krámer et al. | The Effect of Different Factors on the Composition of Human Milk and its Variations. III. Effect of Dietary Fats on the Lipid Composition of Human Milk: Wirkung verschiedener Faktoren auf die Zusammensetzung menschlicher Milch. III. Wirkung des Nahrungsfettes auf den Fettgehalt der menschlichen Milch.–Effet de différents facteurs sur la composition du lait humain et ses variations. III. Effet des graisses alimentaires sur la composition en lipides du lait humain | |
| CN112006113A (en) | Blend oil for regulating blood pressure and reducing blood fat and preparation method thereof | |
| CN110269133A (en) | It is a kind of to improve diet feed of polyunsaturated fatty acid and preparation method thereof and purposes in mutton sheep body | |
| CN114698698A (en) | Medical fat component formula food and preparation method thereof | |
| CN109198253A (en) | For producing feed addictive and the application of high DHA content egg | |
| CN103766507A (en) | Edible oil with health-care function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20220705 |
|
| WW01 | Invention patent application withdrawn after publication |